Q2 2026 saw strong adjusted EPS and EBITDA growth, driven by margin recovery efforts and disciplined expense management. Insperity HRScale launched with early adoption, while guidance for 2026 reflects continued profitability improvement and cautious outlook on healthcare costs.Based on Insperity…
Q2 2026 saw strong adjusted EPS and EBITDA growth, driven by margin recovery efforts and disciplined expense management. Insperity HRScale launched with early adoption, while guidance for 2026 reflects continued profitability improvement and cautious outlook on healthcare costs.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.